Market Awaits Results of Listed Companies, but Unimed Steals the Spotlight
The market is still waiting for the results of listed companies, but attention is shifting to enterprises going through exceptional times, such as Unimed, the pharmaceutical manufacturing unit. Despite the founder's legal troubles, the economic entity has continued to operate smoothly.
Yesterday, Unimed announced that its board of directors reviewed the company's activity during the 2024 fiscal year and approved the individual and consolidated financial statements. The key figures to note are:
- Revenue (excluding tax) of 147,675 MTND, up 8.6% year-over-year
- Net income of 18,458 MTND, compared to 5,582 MTND in 2023
- Group result of 19,371 MTND
The financial statements for the first half of the year and activity indicators showed signs of this improvement, particularly with the strong comeback in the hospital market. Thanks to its experience, Unimed was able to maintain the necessary growth pace to respond to demands from a competitive local market.
The board of directors has decided to convene a General Assembly on August 1, 2025, and propose the distribution of a dividend of 0.570 TND per share. After last year's abstention, the market is expected to react positively to this news. In fact, this is the highest dividend since its introduction on the stock exchange. As a reminder, since the beginning of the year, the title has evolved by 12.2%. Compared to yesterday's closing price, the dividend yield stands at 6.4%.
